The role of presepsin in the estimation of disease severity and assesment the treatment efficiency in patients purulent pyelonephritis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim: to determine the importance of a presepsin plasma level for early identification of urosepsis, assessment the severity and efficiency of therapy. Material and methods. From 2017 to 2018 r. a prospective controlled randomized cohort study with 32 patients (6 men, 26 women) aged from 20 to 60 years was conducted. Patients with diagnosed or suspected purulent pyelonephritis were randomized into two groups depending on the treatment strategy. In Group 1, patients received drug therapy, while in Group 2 surgical treatment was performed due to ineffectiveness of drug therapy. In both groups a level of presepsin was assessed and compared with the clinical manifestation of acute pyelonephritis and the choice of adequate treatment. Results. The mean presepsin level in Group 1 at the admission was 338.4 pg/ml (normal value - 97 pg/ml), while in Group 2 it was 501.125 pg/ml. The presepsin level significantly decreased in both groups on Days 6-7 (p<0.005), to 120.4 pg/ml and 66.875 pg/ml, respectively. Consequently, according to clinical and laboratory data, acute purulent pyelonephritis in patients who received combined therapy was successfully managed without surgical treatment, which was confirmed by the positive changes in body temperature, pain severity, blood analysis (leucocytes, ESR) and urine (protein, leukocytes) due to timely detection of presepsin level. Discussion. Our analysis showed that recovery occurred in both groups, but there are differences in the duration of the disease depending on treatment strategy. Using the presepsin level, we found: In Group 1 the level was 338.4 pg/ml (1.5 times less than in Group 2, p<0.005), which indicates the possibility of systemic infection. In this group the surgical treatment was avoided without any fatal consequences. In Group 2, in patients who were undergone to surgical treatment the mean baseline presepsin level was 501.125 pg/ml, which indicates the moderate risk of systemic infection (severe sepsis) and increased risk of adverse outcomes, therefore, surgical treatment was recommended. Thus, the determination of presepsin level can influence on the choice of treatment strategy. Conclusion. The analysis of presepsin level is necessary for the choice of treatment strategy, since the clinical and laboratory data does not always reflect the changes in the kidneys.

Full Text

Restricted Access

About the authors

Y. G Chernova

FGBOU VO «Altai State Medical University» of the Ministry of Health of Russia

Email: yulya.samchukl4@mail.ru
teaching assistant at the department of urology and andrology with course of Specialized Surgery

A. I Neymark

FGBOU VO «Altai State Medical University» of the Ministry of Health of Russia

Email: urologagmu@mail.ru
Dr.Med.Sci, professor, Department of Specialized Surgery

A. P Momot

FGBU National Research Center of Hematology of the Ministry of Health of Russia

Email: xyzan@yandex.ru
Dr.Med.Sci, professor, chief

References

  1. Horwitz D., McCue T., Mapes A.C., Ajami N.J., Petrosino J.F., Ramig R.F. et al. Decreased microbiota diversity associated with urinary tract infection in a trail of bacterial interference. J. Infect 2015;71(3):358-367. Doi: 10.1016/ j.jinf.2015.05.014.
  2. Яковлев С.В., Суворова М.П. Нозокомиальные инфекции мочевыводящих путей. Урология. 2016;(S3): 45-64
  3. Сурсякова К.И., Сафьянова Т.В. Некоторые эпидемиологические особенности заболеваемости гломерулярными и тубулоинтерстициальными болезнями почек и инфекциями мочевыводящих путей в Алтайском крае. Экспериментальная и клиническая урология. 2017;4:6-10
  4. Глыбочко П.В., Аляев Ю.Г. Интегративная урология. Руководство для врачей. М.: Медфорум, 2014. 432 с.
  5. Алферов С.М., Гришин М.А., Дурникин А.М. Гнойно-деструктивные формы пиелонефрита, осложненные уросепсисом и острой почечной недостаточностью Урологические ведомости. 2016;9-11
  6. Глыбочко П.В., Аляев Ю.Г. Практическая урология М.: ИД «Медфорум». 2012;352 с.
  7. Синякова Л.А., Косова И.В., Дементьева А.В. Принципы профилактики и лечения мочевой инфекции. Урология. 2008;6:79-83
  8. Чеботкевич В.Н., Кайтанджан Е.И., Бурылев В.В., Щетинкина Е.Е. Современные методы лабораторной диагностики сепсиса. Клин микробиол антимикроб химиотер. 2013;15(4):296
  9. Cohen J. Diagnosis of infection in sepsis: An evidencebased review. J. Cohen C. Brun-Buisson. Crit. Care Med. 2004;32(11 (Suppl. 11):466-494.
  10. Endo S., Suzuki Y., Takahashi G., Shozushima T., Ishikura H., Murai A., et al. Presepsin as a powerful monitoring tool for the prognosis and treatment of sepsis: a multicenter prospective study. J. Infect Chemother 2014;20:30-34.
  11. Флетчер Р. Клиническая эпидемиология. Основы доказательной медицины: пер. с англ. Р. Флетчер, С. Флетчер, Э. Вагнер. М.: Медиа Сфера, 1998. 352
  12. Spanuth E., Wilhelm J., Loppnow H. et al. Utility of PATHFAST Presepsin in Septic Patients Admitted to the Emergency Room. 1st Central and Eastern European Sepsis Forum SepsEast Budapest, September 19-23, 2012.
  13. Zweigner J., Schumann R.R., Weber J.R. The role of lipopolysaccharidebinding protein in modulating the innate immune response. Microbes Infect 2006;8(3):946-952. doi: 10.1016/j.micinf.2005.10.006. PMID: 16483818.
  14. Вельков В.В. Пресепсин - новый высокоэффективный биомаркер сепсиса. Клинико-лабораторный консилиум. Научнопрактический журнал. 2012;2(42):56-62
  15. Yaegashi Y., Shirakawa K., Sato N. et al. Evaluation of anewly identified soluble CD14 subtype as a marker for sepsis. J. Infect Chemother. 2005;11(5):234-238.
  16. Endo S., Suzuki Y., Takahashi G. et al. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J. Infect Chemother 2012;18(6):891-7. doi: 10.1007/s10156-012-0435-2. PMID: 22692596.
  17. Martin G.S. Sepsis, severe sepsis and septic shock: changes in incidence, pathogens and outcomes. Expert Rev Anti Infect Ther 2012;10(6):701-706. doi: 10.1586/eri.12.50. PMID: 22734959.
  18. Yu Z., Liu J., Sun Q. et al. The accuracy of the procalcitonin test for the diagnosis of neonatal sepsis: a meta-analysis. Scand. J. Infect. Dis. 2010;42(10):723-733.
  19. Shozushima T., Takahashi G., Matsumoto N., Kojika M., Okamura Y., Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. J. Infect Chemother. 2011;17:764-769.
  20. Батырева Д.Ж., Рамазанова Б.А., Бекназарова А., Алибаева Ж.С., Абдраимова А.А., Нурахова А.Д., Ибраева Н.К., Батырханова Р.С. Вестник КазНМУ. 2016;4-2016
  21. Spanuth E., Ebelt H., Ivandic B. and Werdan K. (2011) Diagnostic and Prognostic Value of Presepsin (Soluble CD14 Subtype) in Emergency Patients with Early Sepsis Using the New Assay PATHFAST Presepsin. Proceedings of 21st International Congress of Clinical Chemistry and Laboratory Medicine, IFCC-WorldLab-EuroMedLab, Berlin, 15-19 May 2011.
  22. Endo S., Suzuki Y., Takahashi G., Shozushima T., Ishikura H., Murai A., Nishida T., Irie Y., Miura M., Iguchi H., Fukui Y., Tanaka K., Nojima T., Okamura Y. Usefulness of presepsin in the diagnosis of sepsis in a multicenter prospective study. J. Infect Chemother. 2012;18(6):891-897. doi: 10.1007/s10156-012-0435-2. Epub 2012 Jun 13.
  23. Vodnik T., Kaljevic G., Tadic T., et al. Presepsin (sCD14-ST) in preoperative diagnosis of abdominal sepsis. Clin. Chem. Lab. Med. 2013;51(10): 2053-2062.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies